Fig. 2
From: Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
CONSORT diagram of men with metastatic prostate cancer with circulating tumor cells examined in this study. Cohort A: men with mCRPC starting abiraterone acetate/prednisone or enzalutamide (pre-ARSI), Cohort B: men with mCRPC who were progressing on enzalutamide or abiraterone acetate/prednisone (post-ARSI), and Cohort C: men with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT) or ADT/docetaxel chemotherapy